A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.

SriBhashyam S, Marsh K, Quartel A, Weng HH, Gershman A, Longo N, Thomas J, Zori R.

Open source

DOI
10.1016/j.ymgmr.2019.100507
Published
2019-08-30
Container
Mol Genet Metab Rep
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ymgmr.2019.100507,
  title = {A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.},
  author = {SriBhashyam S and  Marsh K and  Quartel A and  Weng HH and  Gershman A and  Longo N and  Thomas J and  Zori R.},
  year = {2019},
  journal = {Mol Genet Metab Rep},
  doi = {10.1016/j.ymgmr.2019.100507},
  url = {https://doi.org/10.1016/j.ymgmr.2019.100507}
}

RIS

TY  - JOUR
TI  - A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.
AU  - SriBhashyam S
AU  -  Marsh K
AU  -  Quartel A
AU  -  Weng HH
AU  -  Gershman A
AU  -  Longo N
AU  -  Thomas J
AU  -  Zori R.
PY  - 2019
JO  - Mol Genet Metab Rep
DO  - 10.1016/j.ymgmr.2019.100507
UR  - https://doi.org/10.1016/j.ymgmr.2019.100507
ER  - 

APA

S, S., K, M., A, Q., HH, W., A, G., N, L., J, T., & R., Z. (2019). A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.. Mol Genet Metab Rep. https://doi.org/10.1016/j.ymgmr.2019.100507

Source records